Prospective Randomized Clinical Trial on Oral and Intravenous Antibiotic Prophylaxis in Colorectal Surgery.
- Conditions
- Colorectal Surgery
- Interventions
- Drug: Oral antibiotic drugsDrug: Parenteral prophylaxis
- Registration Number
- NCT04438655
- Lead Sponsor
- University of Turin, Italy
- Brief Summary
Elective colon surgery is considered a clean-contaminated procedure, with a Surgical Site Infection (SSI) rate not inferior to 10%. For many years the role of Mechanical Bowel Preparation (MBP) has been universally recognized as an effective measure to reduce colonic bacterial load and consequently SSI rate, mostly in European Countries. However, in the early 1970s has been demonstrated a further SSI risk reduction in colon surgery if oral non-absorbable antibiotics were added to MBP and for the next 30 years this became the standard of care prior to elective colon surgery, especially in the US. Nowadays, Meta-analyses have demonstrated that MBP does not impact upon postoperative morbidity or mortality, and as such it should not be prescribed routinely. Conversely, recent evidence has suggested that there may be a role for combined MBP and oral antibiotics, or oral antibiotics alone in the prevention of surgical site infection (SSI).
The aim of this trial is to evaluate the efficacy of preoperative oral antibiotics prophylaxis for preventing surgical site infections in elective colorectal surgery.
- Detailed Description
This study is a Multicenter, Prospective, Randomized, Controlled Trial on preoperative oral antibiotics prophylaxis in colorectal surgery.
INCLUSION \& EXCLUSION CRITERIA:
All consecutive patients undergoing elective colorectal resection should be included in the trial.
Exclusion criteria:
* Emergency procedures
* Appendicectomy (unless procedure involves a right hemicolectomy)
* Primarily urological/gynecological or vascular procedure - e.g. ileal conduit, Hartmann's during ovarian surgery, resection during abdominal aortic aneurysm repair.
* Diagnostic laparotomy/laparoscopy without intestinal resection.
* Surgery involving multi-visceral surgery - e.g. pelvic exenteratio
* Controindication for mechanical preparation
* Allergy to used drugs
* Patients who refuse to participate in the study
* Patients with intra-abdominal sepsis before surgery (abscess).
* Patients who received antibiotics for any reason within two weeks prior to surgery.
* Patients who do not comply strictly with the assigned prophylaxis regimen.
* Patients who cannot be followed at least 4 weeks after surgery.
Patients recruitment:
Consecutive eligible patients will be recruited at the outpatient clinic in the participating center by the involved physician (surgeon). All patients fulfilling the inclusion criteria will be informed about the study by the physician. After consent is given, central data acquisition will take place web-based and patients will be randomized in 2 groups and treated according to the study protocol. Patients unable or refusing to provide informed consent will be treated according to current clinical practice.
Primary Outcome:
- Incidence of surgical site infections (superficial or deep)
Secondary Outcomes:
* Perioperative complication
* Anastomotic dehiscence
* Post-operative ileus
* Extra-abdominal complications
* Readmission
* Reoperation
* Length of hospital stay
* Mortality
* Adverse effects of antibiotics (diarrhea, C. difficile infection)
Covariates:
In addition to demographic, procedure and outcome data, the following data will be collected as confounding variables to permit accurate risk adjustment of outcomes.
* The American Society of Anesthesiologists (ASA) score
* Cardiovascular and metabolic co-morbidities (includes chronic obstructive pulmonary disease (COPD), chronic kidney disease (CKD), peripheral vascular disease (PVD) and diabetes mellitus)
* History of previous abdominal surgery
* Preoperative administration of immunosuppressive/steroid therapy
* Preoperative Chemo-RadioTherapy
* Preoperative Albumin Serum Level (g/dL)
Follow-up:
* Patients will be followed for 30 days after surgery. All secondary outcome measures will be recorded if they occurred at any point from post-operative day 0 (day of surgery) to Day 30.
* No change to normal follow-up should take place.
* The follow-up of patients includes a clinical evaluation 30 days after surgical intervention supported by blood analysis (WBC count and CRP), to completely exclude the presence of any infectious complication. Presence of fever and/or WBC count/CRP elevation will require further investigation with radiological imaging and will be considered an infectious post operative complication (SSI or not).
PROJECT TIMELINE:
Data collection will take place in two years. Follow-up data will also be collected for up to 30 days after surgery.
Data Collection and Governance:
Data will be collected and stored online. Communication between the clients and the Server where is hosted the online platform is secured under TLS protocol with an encryption certificate SHA256 with RSA 2048 bits (e 65537). In order to maximize the data protection, the physical HD where is sored the database is encrypted too. Access to the online platform will be possible only previous Login. Each device logged in will be identified and the user will be able to ban the access from a specific device. Each physician will be able to see and modify only the data of patients added from his center. The online platform will check the validity and the correct format of the fields and will generate an excel table to import to the statistic software.
Intervention strategies:
Patients will be randomized to intravenous antibiotic prophylaxis alone or oral antibiotics prepara-tion in association with intravenous antibiotic prophylaxis.
In the group of patients not treated with oral antibiotics standard intravenous prophylaxis will be administered at the time of induction of anesthesia, redosing with prolonged surgery: amoxicil-lin/clavulanic acid 2000/200 mg or, in the event of allergy to penicillin, clindamycin 600 mg + gen-tamycin 2 mg/kg. In case of Chronic Renal Failure dose adjustment will be necessary in presence of Creatinine Clearance respectively \<30 ml/min and \<60 ml/min in accordance to pharmacologic recommendations.
In the other group oral prophylaxis consists of Bimixin (Neomicin + Bacitracin tablet) 25000 UI + 2500 UI). In the postoperative period no more doses will be administered because the drug is not absorbed by gastrointestinal mucosa and its progression from the stomach to the colon is slowed down by post-operative ileus. In this group of patient standard intravenous antibiotic prophylaxis will be administered at induction of anesthesia.
Any mechanical bowel preparation will be administered, as indicated by each center. Surgeon, anesthesiologist and nurse will know if patient had assumed oral antibiotics and intrave-nous antibiotics or intravenous prophylaxis alone. Data concerning SSI rate, infectious complica-tion other than SSI and not infectious complications will be collected during hospital stay. 30 days after the operation blood tests (WBC, CRP) and clinical evaluation will confirm the absence of any infectious complication.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 130
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Oral + Parenteral prophylaxis Oral antibiotic drugs Oral antibiotic drugs: - Bimixin (Neomicin + Bacitracin tablet) 25000 UI + 2500 UI: h. 8-16-24 the day before surgery if the procedure takes place in the morning; h. 16-24-8 if the procedure takes place in the afternoon. Systemic antibiotic drugs: * Amoxicillin - Clavulanic Acid 2000/200 mg at induction of anesthesia, redosing with prolonged surgery. * in case of allergy to penicillin: Clindamycin 600 mg + Gentamycin 2 mg/kg. Oral + Parenteral prophylaxis Parenteral prophylaxis Oral antibiotic drugs: - Bimixin (Neomicin + Bacitracin tablet) 25000 UI + 2500 UI: h. 8-16-24 the day before surgery if the procedure takes place in the morning; h. 16-24-8 if the procedure takes place in the afternoon. Systemic antibiotic drugs: * Amoxicillin - Clavulanic Acid 2000/200 mg at induction of anesthesia, redosing with prolonged surgery. * in case of allergy to penicillin: Clindamycin 600 mg + Gentamycin 2 mg/kg. Only parenteral prophylaxis Parenteral prophylaxis * Amoxicillin - Clavulanic Acid 2000/200 mg at induction of anesthesia, redosing with prolonged surgery. * in case of allergy to penicillin: Clindamycin 600 mg + Gentamycin 2 mg/kg.
- Primary Outcome Measures
Name Time Method Wound infection up to 30 days after surgery Incidence of surgical site infections (superficial or deep)
- Secondary Outcome Measures
Name Time Method Perioperative complication up to 30 days after surgery Incidence of any preoperative complication, assessed as clinically detected
Anastomotic dehiscence up to 30 days after surgery Incidence of anastomotic dehiscence, assessed as clinically detected
Post-operative ileus up to 30 days after surgery length of post-operative ileus, assessed as time to first flatus
Extra-abdominal complications up to 30 days after surgery Iatrogenic problems, bleeding, Cardiac- nephrological - respiratory and gastrointestinal complications
Readmission up to 30 days after surgery incidence of readmission to hospital ward
Reoperation up to 30 days after surgery incidence of reoperation
Length of hospital stay up to 30 days after surgery Hospital stay since colorectal surgery
Mortality up to 30 days after surgery incidence of death for any cause
Adverse Drug Reactions up to 30 days after surgery Allergic reactions / Intolerance
Trial Locations
- Locations (1)
Università degli studi di Torino
🇮🇹Turin, Torino, Italy
Università degli studi di Torino🇮🇹Turin, Torino, Italy